PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-31.37%
Both companies reducing R&D. Martin Whitman would check industry innovation trends.
108.24%
G&A growth while RVPH reduces overhead. John Neff would investigate operational differences.
No Data
No Data available this quarter, please select a different quarter.
-1.12%
Other expenses reduction while RVPH shows 0.00% growth. Joel Greenblatt would examine efficiency.
-3.86%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-3.86%
Both companies reducing total costs. Martin Whitman would check industry trends.
-100.00%
Both companies reducing interest expense. Martin Whitman would check industry trends.
-1.12%
D&A reduction while RVPH shows 0.00% growth. Joel Greenblatt would examine efficiency.
-1.49%
EBITDA decline while RVPH shows 5.85% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
3.86%
Operating income growth 50-75% of RVPH's 7.11%. Martin Whitman would scrutinize operations.
No Data
No Data available this quarter, please select a different quarter.
-73.89%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-1.47%
Pre-tax income decline while RVPH shows 5.94% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Tax expense reduction while RVPH shows 52.58% growth. Joel Greenblatt would examine advantage.
-1.47%
Net income decline while RVPH shows 5.90% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
12.77%
EPS growth exceeding 1.5x RVPH's 7.69%. David Dodd would verify competitive advantages.
13.49%
Diluted EPS growth exceeding 1.5x RVPH's 7.69%. David Dodd would verify competitive advantages.
16.41%
Share count reduction below 50% of RVPH's 2.47%. Michael Burry would check for concerns.
17.29%
Diluted share reduction below 50% of RVPH's 2.47%. Michael Burry would check for concerns.